2025³â 08¿ù 24ÀÏ ÀÏ¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Waters Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector

Compact, compliance-ready mass spectrometer with SmartMS technology ideal for routine accurate-mass measurements with minimal setup or training
´º½ºÀÏÀÚ: 2021-03-16

MILFORD, MASS.-- March 16, 2021 -- Waters Corporation (NYSE:WAT) today released the ACQUITY RDa™ Detector featuring SmartMS™, the company’s newest time-of-flight (TOF) mass spectrometer (MS) for small molecule analysis for pharmaceutical, academic, food, and forensics applications. The accurate-mass ACQUITY™ RDa Detector can be quickly deployed and operated to enable faster and more informed decision-making across a broad set of applications.

“With the ACQUITY RDa Detector, we‘ve taken the complexity of operating a mass spectrometer and put it behind the user interface so that the bench scientist doesn’t have to worry about how it works, but about what to do with the high-quality, reproducible results the detector produces,” said Ian King, Senior Vice President - Global Products, Waters Corporation. “The ACQUITY RDa Detector’s high mass accuracy, automated setup and streamlined workflows offer laboratories a purpose-built high-performance mass spectrometer to support increasingly complex small molecule analysis projects with ease.”

Simplified Set Up and Operation for Confidence and Faster Decision-Making

From setup to results, the ACQUITY RDa Detector is designed for ease-of-use with intuitive system health checks and dedicated results-oriented workflows. With SmartMS, users can identify analytes more accurately and confidently evaluate outcomes with end-to-end robust, reliable workflows for routine applications. Paired with a simple one-button start, the RDa Detector reduces the extent of training, limits downtime, and ensures consistent, reproducible results.

“In the pharma industry, the Waters RDa Detector meets regulatory and production challenges for which a satisfactory solution doesn’t exist,” said Marc Foulon, Director, Pharmaphysic, an analytical development laboratory providing analytical services for the cosmetic, chemical and pharmaceuticals industries.

Big Impact on Small Molecule Analysis

The ACQUITY RDa Detector is optimized for small molecule applications where quality, compliance and data integrity are critical. These include impurity analysis, forced degradation studies, lipid screening, natural products profiling, food contaminant analysis, seized and controlled drug profiling, and general accurate-mass measurements.

For improved usability and faster outcomes, the ACQUITY RDa Detector operates on waters_connect™, an open software platform designed to enhance the value that the RDa brings to laboratories with new functionality, features and software updates. Providing a complete audit trail for acquisition, processing and reporting of data, waters_connect enables seamless compliance and the highest standards of data integrity. With the option of system qualification, the platform is suitable for regulated and non-regulated laboratories alike.

Featuring an array of robust functionalities, simple operation, and a compact form factor, the ACQUITY RDa Detector simplifies the process of making high performance accurate- mass measurements.

The ACQUITY RDa Detector is now available worldwide from Waters and its authorized distributors.



 Àüü´º½º¸ñ·ÏÀ¸·Î

BARRICURE Officially Sponsors SPDU 2025 in Malaysia Collaborating with CHAYA AND LIGHT SDN. BHD. for Local Professional Promotion
LambdaTest and Lab49 Forge a Strategic Partnership to Advance AI-driven Software Testing in Financial Services
HistoSonics Broadens Coverage of Non-Invasive Liver Tumor Therapy to 7 Million Highmark Blue Cross Members
Uptime Survey Reveals AI Ambitions and Challenges Amid Climate and NVIDIA Shifts
Kioxia Sampling UFS Ver. 4.1 Embedded Flash Memory Devices for Automotive Applications
Toshiba Unveils Lens-Reduction CCD Linear Image Sensor with Low Noise to Enhance A3 Multifunction Printer Image Quality
** Chokwang Paint Signs MOU with KOMSCO to Drive Joint R&D in Advanced Coating Technologies

 

AI Medical Service Receives Thai FDA Approval for Gastric Endoscopic D...
BeOne Medicines Earns EMA PRIME Status for BGB-16673 in Waldenstrom¡¯s...
Corpay Cross-Border Using Blockchain Technology to Facilitate Client F...
New AI-Powered Experian Assistant for Model Risk Management Streamline...
LG to Introduce Advanced AI Home Innovations at IFA 2025
Concept Medical Begins MAGICAL-SV IDE Trial with First Patient, Advanc...
The GTDC, CONTEXT and IDC Forge Unprecedented Global Alliance to Deliv...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..